Statistical issues arising in AIDS clinical trials

Abstract In the 11 years since AIDS became a defined disease, programs for the development and evaluation of new drugs for this disease have grown rapidly. Although the fundamental principles that drive the design, conduct, and analysis of clinical trials are as applicable to AIDS as to other diseases, there is no question that we have been confronted with unusually difficult challenges in studying therapeutic approaches for this disease. These include the multiple treatment needs of individual patients, identification of appropriate endpoints, rapidly changing “natural history,” and the need for interaction with an informed and vocal patient community that continues to express dissatisfaction with the pace of research. In this context, statisticians have taken a leadership role in identifying and addressing important methodological issues in the evaluation of AIDS drugs.

[1]  Margaret S. Pepe,et al.  Inference using surrogate outcome data and a validation sample , 1992 .

[2]  J. Bartlett,et al.  Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis , 1991 .

[3]  B. Efron,et al.  Compliance as an Explanatory Variable in Clinical Trials , 1991 .

[4]  J. Robins,et al.  Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .

[5]  S. Zeger,et al.  On estimating efficacy from clinical trials. , 1991, Statistics in medicine.

[6]  S W Lagakos,et al.  Adjusting for early treatment termination in comparative clinical trials. , 1990, Statistics in medicine.

[7]  D P Byar,et al.  Design considerations for AIDS trials. , 1990, The New England journal of medicine.

[8]  P. Volberding,et al.  Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. , 1990, The New England journal of medicine.

[9]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[10]  S. Green,et al.  Issues in the design of drug trials for AIDS. , 1990, Controlled clinical trials.

[11]  T. Fleming.  Evaluation of active control trials in AIDS. , 1990, Journal of acquired immune deficiency syndromes.

[12]  S. Garattini,et al.  The case of GISSI in changing the attitudes and practice of Italian cardiologists. , 1990, Statistics in medicine.

[13]  M. Gail,et al.  On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. , 1990, Journal of acquired immune deficiency syndromes.

[14]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[15]  J. Wittes,et al.  Surrogate endpoints in clinical trials: cardiovascular diseases. , 1989, Statistics in medicine.

[16]  S. Ellenberg,et al.  Surrogate endpoints in clinical trials: cancer. , 1989, Statistics in medicine.

[17]  D. Seigel,et al.  Surrogate endpoints in clinical trials: ophthalmologic disorders. , 1989, Statistics in medicine.

[18]  T R Fleming,et al.  Treatment evaluation in active control studies. , 1987, Cancer treatment reports.

[19]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[20]  Donald W. Marquardt,et al.  The Importance of Statisticians , 1987 .

[21]  Gail Mh.  Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. , 1985 .

[22]  W. Willett,et al.  The 2 × 2 factorial design: Its application to a randomized trial of aspirin and U.S. physicians , 1985 .

[23]  S. Piantadosi,et al.  Factorial designs for randomized clinical trials. , 1985, Cancer treatment reports.

[24]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[25]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[26]  M. Gottlieb,et al.  Pneumocystis pneumonia--Los Angeles. , 2006, MMWR. Morbidity and mortality weekly report.

[27]  F. Muggia,et al.  Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California. , 1981, MMWR. Morbidity and mortality weekly report.

[28]  Book ReviewCardiac Valve Prostheses , 1980 .

[29]  S. Rössner,et al.  Coronary Drug Project Research Group. , 1978, Atherosclerosis.

[30]  P. W. Bowman,et al.  PHS Public Health Service , 1963 .